Ślusarz Magdalena J
Faculty of Chemistry, University of Gdańsk, Gdańsk, Poland.
Biopolymers. 2025 Jan;116(1):e23627. doi: 10.1002/bip.23627. Epub 2024 Sep 17.
The human V1b receptor (V1bR) is primarily expressed in the corticotropic cells of the anterior pituitary where it is involved in the regulation of the hypothalamic-pituitary-adrenal (HPA) axis. The activation of V1bR induces the secretion of adrenocorticotropin hormone (ACTH) from the anterior pituitary cells which, in turn, stimulates the production of cortisol via the adrenal cortex. Clinical studies have demonstrated the chronic dysfunction of the HPA axis in patients with several psychiatric disorders. Thus, the inhibition of the V1b receptor and normalizing the HPA axis hyperactivity is a promising approach to the treatment of many stress-related disorders such as anxiety and depression. Nelivaptan is a selective V1bR antagonist that can be used for this purpose and an excellent molecule to study how antagonists interact with V1bR, especially since in recent years the experimental structures of vasopressin V2 and oxytocin receptors were solved, providing high-similarity templates for homology modeling of V1bR. Therefore, in this work, six independent molecular dynamics simulations of a V1bR-nelivaptan complex in a fully hydrated lipid bilayer, yielding a total simulation time of 6.0 μs, have been conducted. In the lowest-energy complexes obtained in this work and proposed to be the most probable structure of the V1bR-nelivaptan complex, the location of the ligand inside the receptor pocket is very similar to that of the other ligands observed in the experimental structures of the vasopressin/oxytocin receptor family. The receptor-ligand interaction has been analyzed and described, revealing the details of the molecular mechanism of this antagonist binding to V1bR and a probable contribution of L200 and T203 to binding selectivity.
人类V1b受体(V1bR)主要表达于垂体前叶的促肾上腺皮质激素细胞中,参与下丘脑-垂体-肾上腺(HPA)轴的调节。V1bR的激活诱导垂体前叶细胞分泌促肾上腺皮质激素(ACTH),进而通过肾上腺皮质刺激皮质醇的产生。临床研究表明,几种精神疾病患者的HPA轴存在慢性功能障碍。因此,抑制V1b受体并使HPA轴亢进正常化是治疗许多与应激相关疾病(如焦虑和抑郁)的一种有前景的方法。奈利妥坦是一种可用于此目的的选择性V1bR拮抗剂,是研究拮抗剂与V1bR相互作用的优秀分子,特别是近年来血管加压素V2和催产素受体的实验结构得到了解析,为V1bR的同源建模提供了高度相似的模板。因此,在这项工作中,我们对V1bR-奈利妥坦复合物在完全水合的脂质双层中进行了六次独立的分子动力学模拟,总模拟时间为6.0微秒。在这项工作中获得的能量最低的复合物中,该复合物被认为是V1bR-奈利妥坦复合物最可能的结构,配体在受体口袋内的位置与在血管加压素/催产素受体家族实验结构中观察到的其他配体非常相似。我们对受体-配体相互作用进行了分析和描述,揭示了这种拮抗剂与V1bR结合的分子机制细节以及L200和T203对结合选择性的可能贡献。